The Patent Finder

Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Pancreatic Adenocarcinoma

Astellas Pharma Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 4 of these applications claim priority to application PCT/EP2014/000433, filed Feb 18, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 9,770,487Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Pancreatic Adenocarcinoma
In force
 · High confidence
Astellas Pharma Inc.In force
High confidence
US 10,314,890Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Pancreatic Cancer
In force
 · High confidence
Astellas Pharma Inc.In force
High confidence
US 10,946,069Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Pancreatic Cancer
In force
 · High confidence
Astellas Pharma Inc.In force
High confidence
US 11,826,402Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Metastatic Pancreatic Adenocarcinoma
In force
 · High confidence
Astellas Pharma Inc.In force
High confidence
Application 18/455,469Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Metastatic Pancreatic Adenocarcinoma
Pending
Not granted
Astellas Pharma Inc.PendingNot granted
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Astellas Pharma Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited